-
-
-
-
-
-
-
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Capricor shares five-year deramiocel data at DMD conference
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result
-
-
-
-
-
-
-
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Lowered to $22 at Oppenheimer
-
-
-
-
-
-
-
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
-
15,649 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

